191 related articles for article (PubMed ID: 23510463)
1. Targeting erythropoietin for chronic neurodegenerative diseases.
Chong ZZ; Shang YC; Mu Y; Cui S; Yao Q; Maiese K
Expert Opin Ther Targets; 2013 Jun; 17(6):707-20. PubMed ID: 23510463
[TBL] [Abstract][Full Text] [Related]
2. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.
Held MA; Greenfest-Allen E; Su S; Stoeckert CJ; Stokes MP; Wojchowski DM
Cell Signal; 2020 May; 69():109554. PubMed ID: 32027948
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the intracellular signaling of erythropoietin in neuronal cells.
Digicaylioglu M
Methods Mol Biol; 2013; 982():175-86. PubMed ID: 23456869
[TBL] [Abstract][Full Text] [Related]
4. Effects of supplemental erythropoietin on its receptor expression and signal transduction pathways in rat model of retinal detachment.
Xie Z; Chen F; Wu X; Zhuang C; Zhu J; Wang J; Ji H; Wang Y; Hua X
Curr Eye Res; 2012 Feb; 37(2):138-44. PubMed ID: 22251399
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
[TBL] [Abstract][Full Text] [Related]
6. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
7. β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase.
Su KH; Shyue SK; Kou YR; Ching LC; Chiang AN; Yu YB; Chen CY; Pan CC; Lee TS
J Cell Physiol; 2011 Dec; 226(12):3330-9. PubMed ID: 21321940
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades.
Chong ZZ; Kang JQ; Maiese K
J Cereb Blood Flow Metab; 2002 May; 22(5):503-14. PubMed ID: 11973422
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades.
Digicaylioglu M; Lipton SA
Nature; 2001 Aug; 412(6847):641-7. PubMed ID: 11493922
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia.
Knabe W; Sirén AL; Ehrenreich H; Kuhn HJ
Anat Embryol (Berl); 2005 Oct; 210(3):209-19. PubMed ID: 16151855
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8.
Chong ZZ; Lin SH; Kang JQ; Maiese K
J Neurosci Res; 2003 Mar; 71(5):659-69. PubMed ID: 12584724
[TBL] [Abstract][Full Text] [Related]
14. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin: new directions for the nervous system.
Maiese K; Chong ZZ; Shang YC; Wang S
Int J Mol Sci; 2012; 13(9):11102-11129. PubMed ID: 23109841
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin: cytoprotection in vascular and neuronal cells.
Chong ZZ; Kang JQ; Maiese K
Curr Drug Targets Cardiovasc Haematol Disord; 2003 Jun; 3(2):141-54. PubMed ID: 12769640
[TBL] [Abstract][Full Text] [Related]
17. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin.
Dunlop EA; Percy MJ; Boland MP; Maxwell AP; Lappin TR
Neurodegener Dis; 2006; 3(1-2):94-100. PubMed ID: 16909043
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
Merelli A; Czornyj L; Lazarowski A
Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor.
Miller JL; Church TJ; Leonoudakis D; Lariosa-Willingham K; Frigon NL; Tettenborn CS; Spencer JR; Punnonen J
Mol Pharmacol; 2015 Aug; 88(2):357-67. PubMed ID: 26018904
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.
Sirén AL; Fasshauer T; Bartels C; Ehrenreich H
Neurotherapeutics; 2009 Jan; 6(1):108-27. PubMed ID: 19110203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
